{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:12:39Z","timestamp":1792109559755,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,11,19]],"date-time":"2010-11-19T00:00:00Z","timestamp":1290124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1007\/s00415-010-5823-x","type":"journal-article","created":{"date-parts":[[2010,11,18]],"date-time":"2010-11-18T18:26:38Z","timestamp":1290104798000},"page":"746-752","source":"Crossref","is-referenced-by-count":31,"title":["Comparison of muscle ultrastructure in myasthenia gravis with anti-MuSK and anti-AChR antibodies"],"prefix":"10.1007","volume":"258","author":[{"given":"Giovanna","family":"Cenacchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Papa","family":"Valentina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanin","family":"Marina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegoraro","family":"Elena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelini","family":"Corrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,19]]},"reference":[{"key":"5823_CR1","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","volume":"330","author":"DB Drachman","year":"1994","unstructured":"Drachman DB (1994) Myasthenia gravis. N Engl J Med 330:1797\u20131810","journal-title":"N Engl J Med"},{"key":"5823_CR2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/mus.20030","volume":"29","author":"JC Keesey","year":"2004","unstructured":"Keesey JC (2004) Clinical evaluation and management of myasthenia gravis. Muscle Nerve 29:484\u2013505","journal-title":"Muscle Nerve"},{"key":"5823_CR3","unstructured":"Angelini C (1994) Miastenia grave: progressi clinici. Piccin Editor, pp 209\u2013220"},{"key":"5823_CR4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"III Jaretski","year":"2000","unstructured":"Jaretski III, Bahron RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Neurology 55:16\u201323","journal-title":"Neurology"},{"key":"5823_CR5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0140-6736(86)92259-2","volume":"1","author":"S Mossman","year":"1986","unstructured":"Mossman S, Vincent A, Newsom-Davis J (1986) Myasthenia gravis without acetylcholine receptor antibody: a distinct disease entity. Lancet 1:116\u2013119","journal-title":"Lancet"},{"key":"5823_CR6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"W Hoch","year":"2001","unstructured":"Hoch W, McConville J, Helms J et al (2001) Auto-antibodies to the receptor tyrosin-kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365\u2013368","journal-title":"Nat Med"},{"key":"5823_CR7","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/jnnp.2004.043125","volume":"76","author":"Y Nemoto","year":"2005","unstructured":"Nemoto Y, Kuwabara S, Misawa N et al (2005) Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis. J Neurol Neurosurg Psychiatry 76:714\u2013718","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5823_CR8","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.clinph.2006.03.028","volume":"117","author":"A Rostedt Punga","year":"2006","unstructured":"Rostedt Punga A, Ahlqvist K, Bartoccioni E et al (2006) Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes. Clin Neurophysiol 117:1434\u20131443","journal-title":"Clin Neurophysiol"},{"key":"5823_CR9","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0092-8674(00)81251-9","volume":"85","author":"TM DeChiara","year":"1996","unstructured":"DeChiara TM, Bowen DC, Valenzuela DM et al (1996) The receptor tyrosin kinase MuSK is required for neuromuscular junction formation in vivo. Cell 85:501\u2013512","journal-title":"Cell"},{"key":"5823_CR10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/01.wnl.0000254620.45529.97","volume":"68","author":"F Deymeer","year":"2007","unstructured":"Deymeer F, Gungor-Tuncer O, Yilmaz V et al (2007) Clinical comparison of anti-MuSK vs anti-AChR-positive and seronegative myasthenia gravis. Neurology 68:609\u2013611","journal-title":"Neurology"},{"key":"5823_CR11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1468-1331.2005.01137.x","volume":"12","author":"F Romi","year":"2005","unstructured":"Romi F, Aarli, Gilhus NE (2005) Seronegative myasthenia gravis: disease severity and prognosis. Eur J Neurol 12:413\u2013418","journal-title":"Eur J Neurol"},{"key":"5823_CR12","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/WCO.0b013e32833c0982","volume":"23","author":"JT Guptill","year":"2010","unstructured":"Guptill JT, Sanders DB (2010) Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol 23:530\u2013535","journal-title":"Curr Opin Neurol"},{"key":"5823_CR13","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","volume":"60","author":"DB Sanders","year":"2003","unstructured":"Sanders DB, El-Salem K, Massey JM et al (2003) Clinical aspects of MuSK antibody positive seronegative MG. Neurology 60:1978\u20131980","journal-title":"Neurology"},{"key":"5823_CR14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2990.2008.00965.x","volume":"35","author":"S Martignago","year":"2009","unstructured":"Martignago S, Fanin M, Albertini E et al (2009) Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR. Neuropathol Appl Neurobiol 35:103\u2013110","journal-title":"Neuropathol Appl Neurobiol"},{"key":"5823_CR15","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awl095","volume":"129","author":"ME Farrugia","year":"2006","unstructured":"Farrugia ME, Robson MD, Clover L et al (2006) MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 129:1481\u20131492","journal-title":"Brain"},{"key":"5823_CR16","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1212\/01.WNL.0000128048.23930.1D","volume":"62","author":"D Selcen","year":"2004","unstructured":"Selcen D, Fukuda T, Shen XM et al (2004) Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology 62:1945\u20131950","journal-title":"Neurology"},{"key":"5823_CR17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/mus.21642","volume":"42","author":"EH Niks","year":"2010","unstructured":"Niks EH, Kuks JBM, Wokke JHJ et al (2010) Pre-postsynaptic neuromuscular junction abnormalities in MuSK. Myasthenia Muscle Nerve 42:283\u2013288","journal-title":"Myasthenia Muscle Nerve"},{"key":"5823_CR18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.4103\/0028-3886.43449","volume":"56","author":"A Vincent","year":"2008","unstructured":"Vincent A (2008) Autoimmune disorders of the neuromuscular junction. Neurol India 56:305\u2013313","journal-title":"Neurol India"},{"key":"5823_CR19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/ana.20341","volume":"57","author":"H Shiraishi","year":"2005","unstructured":"Shiraishi H, Motomura M, Yoshimura T et al (2005) Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 57:289\u2013293","journal-title":"Ann Neurol"},{"key":"5823_CR20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1385\/JMN:30:1:223","volume":"30","author":"Q Wang","year":"2006","unstructured":"Wang Q, Zhang B, Xiong WC et al (2006) MuSK signalling at the neuromuscular junction. J Mol Neurosci 30:223\u2013226","journal-title":"J Mol Neurosci"},{"key":"5823_CR21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jneuroim.2005.08.016","volume":"170","author":"O Benveniste","year":"2005","unstructured":"Benveniste O, Jacobson L, Farrugia ME et al (2005) MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscles in vivo. J Neuroimmunol 170:41\u201348","journal-title":"J Neuroimmunol"},{"key":"5823_CR22","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jneuroim.2007.01.010","volume":"185","author":"ME Farrugia","year":"2007","unstructured":"Farrugia ME, Bonifati DM, Clover L et al (2007) Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures. J Neuroimmunol 185:136\u2013144","journal-title":"J Neuroimmunol"},{"key":"5823_CR23","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1001\/archneur.62.6.1002","volume":"62","author":"JB Caress","year":"2005","unstructured":"Caress JB, Hunt CH, Batish SD (2005) Anti-MuSK myasthenia gravis presenting with purely ocular findings. Arch Neurol 62:1002\u20131003","journal-title":"Arch Neurol"},{"key":"5823_CR24","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00115-003-1672-5","volume":"75","author":"B Hain","year":"2004","unstructured":"Hain B, Hanisch F, Deschauer M (2004) Seronegative myasthenia with antibodies against muscle-specific tyrosin kinase. Nervenartz 75:362\u2013367","journal-title":"Nervenartz"},{"key":"5823_CR25","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/jnnp.2004.052415","volume":"76","author":"D Lavrnic","year":"2005","unstructured":"Lavrnic D, Losen M, Vujic A et al (2005) The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiat 76:1099\u20131102","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"5823_CR26","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.clinph.2005.06.003","volume":"116","author":"DE Stickler","year":"2005","unstructured":"Stickler DE, Massey JM, Sanders DB (2005) MuSK- antibody positive myasthenia gravis: clinical and electrodiagnostic patterns. Clin Neurophysiol 116:2065\u20132068","journal-title":"Clin Neurophysiol"},{"key":"5823_CR27","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1196\/annals.1405.037","volume":"1132","author":"J Soltys","year":"2008","unstructured":"Soltys J, Gong B, Kaminski HJ et al (2008) Extraocular muscle susceptibility to myasthenia gravis. Unique immunological environment? Ann N Y Acad Sci 1132:220\u2013224","journal-title":"Ann N Y Acad Sci"},{"key":"5823_CR28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.nmd.2004.10.002","volume":"15","author":"CY Yu Wai Man","year":"2005","unstructured":"Yu Wai Man CY, Chinnery PF, Griffiths PG (2005) Extraocular muscles have fundamentally distinct properties that make them selectively vulnerable to certain disorders. Neuromuscul Disord 15:17\u201323","journal-title":"Neuromuscul Disord"},{"key":"5823_CR29","doi-asserted-by":"crossref","first-page":"e5390","DOI":"10.1371\/journal.pone.0005390","volume":"4","author":"L Dupuis","year":"2009","unstructured":"Dupuis L, Gonzales de Aguilar JL, Echaniz-Laguna A et al (2009) Muscle mitochondrial uncoupling dismantles neuromuscular junction and triggers distal degeneration of motor neurons. Plos One 4:e5390","journal-title":"Plos One"},{"key":"5823_CR30","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.neuroscience.2006.09.022","volume":"143","author":"K Xu","year":"2006","unstructured":"Xu K, Jha S, Hoch W, Dryer SE (2006) Delayed synapsing muscles are more severely affected in an experimental model of MuSK-induced myasthenia gravis. Neuroscience 143:655\u2013659","journal-title":"Neuroscience"},{"key":"5823_CR31","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.neuron.2009.01.030","volume":"61","author":"AF MacAskill","year":"2009","unstructured":"MacAskill AF, Rinholm JE, Twelvetrees AE et al (2009) Miro1 is a calcium sensor for glutamate receptor-dependent localization of mitochondrial at synapses. Neuron 61:541\u2013555","journal-title":"Neuron"},{"key":"5823_CR32","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0891-5849(01)00517-2","volume":"30","author":"V Pesce","year":"2001","unstructured":"Pesce V, Cormio A, Fracasso F et al (2001) Age-related mitochondrial genotypic and phenotypic alterations in human skeletal muscles. Free Rad Biol Med 30:1223\u20131233","journal-title":"Free Rad Biol Med"},{"issue":"1","key":"5823_CR33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1756-6606-1-18","volume":"1","author":"GC Dobbins","year":"2008","unstructured":"Dobbins GC, Luo S, Yang Z et al (2008) Alpha-actinin interacts with rapsyn in agrin-stimulated AChR clustering. Mol Brain 1(1):18","journal-title":"Mol Brain"},{"key":"5823_CR34","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1136\/jnnp.2008.169367","volume":"81","author":"J Spillane","year":"2010","unstructured":"Spillane J, Beeson DJ, Kullmann DM (2010) Myasthenia and related disorders of the neuromuscular junction. J Neurol Neurosurg Psychiatry 81:850\u2013857","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5823_CR35","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/01.wco.0000180660.57801.3f","volume":"18","author":"A Vincent","year":"2005","unstructured":"Vincent A, Leite MI (2005) Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol 18:519\u2013525","journal-title":"Curr Opin Neurol"},{"key":"5823_CR36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1474-4422(03)00306-5","volume":"2","author":"A Vincent","year":"2003","unstructured":"Vincent A, Bowen J, Newsom-Davis J et al (2003) Seronegative generalised myasthenia gravis: clinical features, antibodies, and their target. Lancet Neurol 2:99\u2013106","journal-title":"Lancet Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-010-5823-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-010-5823-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-010-5823-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T19:13:03Z","timestamp":1559070783000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-010-5823-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,19]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["5823"],"URL":"https:\/\/doi.org\/10.1007\/s00415-010-5823-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,19]]}}}